Paris - Delayed Quote EUR

Ikonisys S.A. (ALIKO.PA)

1.5850

-0.0050

(-0.31%)

As of 11:20:58 AM GMT+2. Market Open.

Ikonisys Finalized a Capital Increase Through the Offsetting of Debt

PARIS, May 02, 2025--Regulatory News: Ikonisys SA (Euronext Growth Paris: ALIKO), a company specializing in the early and accurate detection of cancers through a unique, fully automated solution for medical analysis laboratories (the "Issuer"), today announces a capital increase of €350k through the offsetting of part of the debt owed to two shareholders, including Cambria Equity Partners LP, and the issue of 233,334 new shares of the Company.

Business Wire 18 days ago

ALIKO.PA
-0.31%
Ikonisys Announces the Postponement of the Publication of Its 2024 Annual Financial Report

PARIS, April 25, 2025--Regulatory News: ALIKO SCIENTIFIC (Ikonisys SA) (Euronext Growth Paris: ALIKO), a company specializing in the early and accurate detection of cancers through a unique, fully automated solution for medical analysis laboratories, today announces the postponement of the publication of its 2024 annual financial report, initially scheduled on April 30, 2025, to no later than May 31, 2025.

Business Wire 25 days ago

ALIKO.PA
-0.31%
Ikonisys SA: Hospitex International Launches Urine24, the First-Online Urinary Cytology Test Platform, Marking a Breakthrough in Early Bladder Cancer Diagnosis in Italy

FLORENCE, Italy & PARIS, April 03, 2025--Regulatory News: ALIKO SCIENTIFIC (Ikonisys SA) (Euronext Growth Paris: ALIKO), announces that its Italian subsidiary Hospitex International has launched Urine24.com, the first online-available urinary cytology test for early bladder cancer diagnosis. The service is now available through its official website offering a non-invasive, fast, and highly reliable solution for millions of Italians.

Business Wire last month

ALIKO.PA
-0.31%
Ikonisys SA Wins Public Tender with F. Miulli Regional General Hospital for Pathological Anatomy

PARIS, March 10, 2025--Regulatory News: Hospitex, the Italian leader in the production of Cytology medical devices and fully owned subsidiary of ALIKO SCIENTIFIC (Ikonisys SA) (Euronext Growth Paris: ALIKO), a company specializing in the early and accurate detection of cancers through a unique, fully automated solution for medical analysis laboratories, has secured a prestigious public tender from the Ecclesiastical Entity F. Miulli Regional General Hospital. This contract marks a significant mi

Business Wire 2 months ago

ALIKO.PA
-0.31%
Ikonisys Finalized a Capital Increase Through a Private Placement

PARIS, February 27, 2025--Regulatory News: Ikonisys SA (Euronext Growth Paris: ALIKO), a company specializing in the early and accurate detection of cancers through a unique, fully automated solution for medical analysis laboratories (the "Issuer"), today announces the completion of a capital increase of €500k by way of a private placement with a specialized investor.

Business Wire 2 months ago

ALIKO.PA
-0.31%
Ikonisys’ Subsidiary Hospitex Secures a Major UN-Funded Contract for Hospital IT and Networking Systems in Ethiopia

PARIS, February 05, 2025--Regulatory News: ALIKO SCIENTIFIC (Ikonisys SA) (Euronext Growth Paris: ALIKO), today announces that its subsidiary Hospitex, the Italian leader in the production of medical devices, has secured a major contract to supply IT and networking systems for hospitals in Adwa, Ethiopia.

Business Wire 3 months ago

ALIKO.PA
-0.31%
Ikonisys Secures U.S. Patent for "Automated Fluorescence Microscopy Method to Determine the Efficacy of Cancer and Hyperplasia Treatments"

PARIS, January 27, 2025--Regulatory News: Ikonisys Inc., a leader in advanced cell-based diagnostic solutions fully owned by ALIKO SCIENTIFIC (Ikonisys SA) (Euronext Growth Paris: ALIKO), is proud to announce the grant of a new U.S. patent by the United States Patent and Trademark Office (USPTO) entitled "Automated Fluorescence Microscopy Method to Determine the Efficacy of Cancer and Hyperplasia Treatments".

Business Wire 3 months ago

ALIKO.PA
-0.31%
Ikonisys: Hospitex Secures Major Public Tender for "Gaetano Martino" University Hospital in Messina

PARIS, January 15, 2025--Regulatory News: Hospitex, the Italian leader in the production of medical devices and a subsidiary of ALIKO SCIENTIFIC (Ikonisys SA) (Euronext Growth Paris: ALIKO), today announces that it has secured a public tender for the Azienda Ospedaliera Universitaria "Gaetano Martino" in Messina, Italy.

Business Wire 4 months ago

ALIKO.PA
-0.31%
Ikonisys Finalized the Acquisition of Hospitex with the Issuance of 2M New Shares to ETH Scientific

PARIS, December 31, 2024--Regulatory News: Ikonisys SA (Euronext Growth Paris: ALIKO), a company specializing in the early and accurate detection of cancers through a unique, fully automated solution for medical analysis laboratories (the "Issuer"), today announces that it has completed the acquisition of Hospitex International Srl, with the issuance of 2 million new Ikonisys shares to ETH Scientific Srl, the former owner of Hospitex.

Business Wire 4 months ago

ALIKO.PA
-0.31%
The Ikonisys Group Unveils its New Vision and Strategy Under the Brand "ALIKO SCIENTIFIC"

PARIS, December 04, 2024--Regulatory News: ALIKO SCIENTIFIC (Ikonisys SA) (Euronext Growth Paris: ALIKO), a company specializing in the early and accurate detection of cancers through a unique fully automated solution for medical analysis laboratories, is proud to announce the launch of its new vision and strategy under the brand "ALIKO SCIENTIFIC" (www.alikoscientific.com). This pivotal development introduces a renewed corporate identity and business vision, marking the Group’s transformation i

Business Wire 5 months ago

ALIKO.PA
-0.31%
Ikonisys Group Secures Major Public Contract for Ikoniscope20 Robotic Microscope in Italy

PARIS, November 25, 2024--Regulatory News: Ikonisys SA (Euronext Growth Paris: ALIKO), a company specializing in the early and accurate detection of cancers through a unique fully automated solution for medical analysis laboratories, today announces the achievement of a significant milestone in its commercial journey through its wholly owned subsidiary, Hospitex. Just eight months after its integration into the Group, Hospitex has been awarded another prestigious public tender to supply the inno

Business Wire 5 months ago

ALIKO.PA
-0.31%
Ikonisys Completed a Capital Increase Through a Private Placement

PARIS, November 19, 2024--Regulatory News: Ikonisys SA (Euronext Growth Paris: ALIKO), a company specializing in the early and accurate detection of cancers through a unique, fully automated solution for medical analysis laboratories (the "Issuer"), today announces that it has completed a capital increase of €200k, by way of a private placement.

Business Wire 5 months ago

ALIKO.PA
-0.31%
Ikonisys Group enters Central America Market through a Partnership and Distribution Agreement with Green Med Panama

PARIS, November 18, 2024--Regulatory News: Ikonisys SA (Euronext Growth Paris: ALIKO), a company specializing in the early and accurate detection of cancers through a unique fully automated solution for medical analysis laboratories, today announces the signing of a distribution agreement with Green Med, a major distributor of medical devices in Panama and Central America. This collaboration is part of a strategic initiative, which aims at bringing innovative cytological and oncological diagnost

Business Wire 5 months ago

ALIKO.PA
-0.31%
Ikonisys Group Renews Agreement as European Authorized Representative and Importer for Novodiax’s CE IVD-Certified Real-Time Immunohistochemistry Technology in Oncological Diagnostics and Organ Transplant Safety

PARIS, November 12, 2024--Regulatory News: Ikonisys SA (Euronext Growth Paris: ALIKO), a company specializing in the early and accurate detection of cancers through a unique fully automated solution for medical analysis laboratories, is pleased to announce that Hospitex has renewed its contract as the European Authorized Representative and Importer for Novodiax. Novodiax, a U.S.-based company specialized in immunohistochemistry, is the exclusive provider of CE IVD-IHC (in vitro diagnostics and i

Business Wire 6 months ago

ALIKO.PA
-0.31%
Ikonisys to Start Collaboration with SYNLAB Italy to Introduce Ikoniscope in Pathology Laboratories

PARIS, November 04, 2024--Regulatory News: Ikonisys (Euronext Growth Paris: ALIKO), a company specializing in the early and accurate detection of cancers through a unique, fully automated solution for medical analysis laboratories, today announces the start of a collaboration with SYNLAB Italy, part of SYNLAB Group, a leader in medical diagnostic services and specialty testing in Europe, for the implementation of Ikoniscope, the advanced platform based on Fluorescence In Situ Hybridization (FISH

Business Wire 6 months ago

ALIKO.PA
-0.31%
Ikonisys Publishes Its 2024 Half-Year Financial Results

PARIS, October 31, 2024--Regulatory News: Ikonisys SA (Euronext Growth Paris: ALIKO), a company specializing in the early and accurate detection of cancers through a unique fully automated solution for medical analysis laboratories, today announces its financial results for the first half of the year ended June 30, 2024, approved by the Board of Directors on October 29, 2024, and provides an update on the latest developments.

Business Wire 6 months ago

ALIKO.PA
-0.31%
Ikonisys Announces That Hospitex International Won the Public Tender of the Prestigious U.O.C. Pathological Anatomy of Enna in Italy

PARIS, October 10, 2024--Regulatory News: Ikonisys SA (Euronext Growth Paris: ALIKO), a company specializing in the early and accurate detection of cancer through fully automated solutions for medical laboratories, is pleased to announce that its fully-owned company Hospitex International has successfully won the public tender for the in-service supply of diagnostic systems to the U.O.C. Pathological Anatomy Unit in Enna, Italy.

Business Wire 7 months ago

ALIKO.PA
-0.31%
Successful 2024 ISO 13485 Certification Maintenance Strengthening Ikonisys’ Strong Market Position and Growth Potential

PARIS, October 03, 2024--Regulatory News: Ikonisys SA (Euronext Growth Paris: ALIKO), a company specializing in the early and accurate detection of cancers through a unique, fully automated solution for medical analysis laboratories, today announces the successful maintenance of its ISO 13485 certification. This milestone strengthens the Company’s QMS (Quality Management System) and enhances its competitive edge in global markets, driving confidence in both operational excellence and future grow

Business Wire 7 months ago

ALIKO.PA
-0.31%
Ikonisys Announces the Results of its Ordinary Annual and Extraordinary General Meeting of September 30, 2024

PARIS, October 01, 2024--Regulatory News: Ikonisys SA (Euronext Growth Paris: ALIKO), a company specializing in the early and accurate detection of cancers through a unique, fully automated solution for medical analysis laboratories, announces that all the resolutions submitted to the Ordinary Annual and Extraordinary General Meeting held on September 30, 2024 (the "CGM") have been adopted by the shareholders, in accordance with the recommendations of the Board of Directors, and in particular th

Business Wire 7 months ago

ALIKO.PA
-0.31%
Ikonisys SA: Postponement of the Shareholders’ Meeting to September 30, 2024 and Amendment of the Agenda

PARIS, September 12, 2024--Regulatory News: Ikonisys SA (Euronext Growth Paris: ALIKO), a company specializing in the early and accurate detection of cancers through a unique, fully automated solution for medical analysis laboratories (the "Issuer"), today announces the postponement of its Shareholders’ Meeting, initially scheduled on September 25, 2024, to September 30, 2024, and the amendment of the Shareholders’ Meeting agenda by the Board of Directors of the Issuer in order to add a resoluti

Business Wire 8 months ago

ALIKO.PA
-0.31%

Performance Overview

Return	ALIKO.PA	CAC 40 (^FCHI)
YTD	+6.38%	+6.85%
1-Year	+6.38%	-3.13%
3-Year	-41.08%	+25.48%

News

Life

Entertainment

Finance

Sports

New on Yahoo

Yahoo Finance

Ikonisys S.A. (ALIKO.PA)

Ikonisys Finalized a Capital Increase Through the Offsetting of Debt

Ikonisys Announces the Postponement of the Publication of Its 2024 Annual Financial Report

Ikonisys SA: Hospitex International Launches Urine24, the First-Online Urinary Cytology Test Platform, Marking a Breakthrough in Early Bladder Cancer Diagnosis in Italy

Ikonisys SA Wins Public Tender with F. Miulli Regional General Hospital for Pathological Anatomy

Ikonisys Finalized a Capital Increase Through a Private Placement

Ikonisys’ Subsidiary Hospitex Secures a Major UN-Funded Contract for Hospital IT and Networking Systems in Ethiopia

Ikonisys Secures U.S. Patent for "Automated Fluorescence Microscopy Method to Determine the Efficacy of Cancer and Hyperplasia Treatments"

Ikonisys: Hospitex Secures Major Public Tender for "Gaetano Martino" University Hospital in Messina

Ikonisys Finalized the Acquisition of Hospitex with the Issuance of 2M New Shares to ETH Scientific

The Ikonisys Group Unveils its New Vision and Strategy Under the Brand "ALIKO SCIENTIFIC"

Ikonisys Group Secures Major Public Contract for Ikoniscope20 Robotic Microscope in Italy

Ikonisys Completed a Capital Increase Through a Private Placement

Ikonisys Group enters Central America Market through a Partnership and Distribution Agreement with Green Med Panama

Ikonisys Group Renews Agreement as European Authorized Representative and Importer for Novodiax’s CE IVD-Certified Real-Time Immunohistochemistry Technology in Oncological Diagnostics and Organ Transplant Safety

Ikonisys to Start Collaboration with SYNLAB Italy to Introduce Ikoniscope in Pathology Laboratories

Ikonisys Publishes Its 2024 Half-Year Financial Results

Ikonisys Announces That Hospitex International Won the Public Tender of the Prestigious U.O.C. Pathological Anatomy of Enna in Italy

Successful 2024 ISO 13485 Certification Maintenance Strengthening Ikonisys’ Strong Market Position and Growth Potential

Ikonisys Announces the Results of its Ordinary Annual and Extraordinary General Meeting of September 30, 2024

Ikonisys SA: Postponement of the Shareholders’ Meeting to September 30, 2024 and Amendment of the Agenda

Performance Overview